VIATRIS INC. (VTRS) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 1.74B USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 11.61B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 35.04B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $1.74B | $11.61B | (m) | (m) | $35.04B | (m) |
| 2026-03-31 | (m) | (m) | $1.93B | $12.41B | (m) | (m) | $36.83B | (m) |
| 2025-12-31 | (m) | (m) | $1.93B | $12.48B | (m) | $1.36B | $37.19B | (m) |
| 2025-09-30 | (m) | (m) | $1.95B | $12.49B | (m) | (m) | $37.92B | (m) |
| 2025-06-30 | (m) | (m) | $1.68B | $12.79B | (m) | (m) | $38.41B | (m) |
| 2025-03-31 | (m) | (m) | $8.50M | $14.18B | (m) | (m) | $38.47B | (m) |
| 2024-12-31 | (m) | (m) | $8.30M | $14.04B | (m) | $772.80M | $41.50B | (m) |
| 2024-09-30 | (m) | (m) | $1.45B | $14.30B | (m) | (m) | $44.75B | (m) |
| 2024-06-30 | (m) | (m) | $2.37B | $14.73B | (m) | (m) | $45.33B | (m) |
| 2024-03-31 | (m) | (m) | $1.90B | $16.07B | (m) | (m) | $47.34B | (m) |
| 2023-12-31 | (m) | (m) | $1.94B | $16.19B | (m) | $1.03B | $47.69B | (m) |
| 2023-09-30 | (m) | (m) | $1.31B | $17.08B | (m) | (m) | $48.74B | (m) |
| 2023-06-30 | (m) | (m) | $1.33B | $17.25B | (m) | (m) | $48.70B | (m) |
| 2023-03-31 | (m) | (m) | $508.70M | $18.07B | (m) | (m) | $49.29B | (m) |
| 2022-12-31 | (m) | (m) | $1.26B | $18.02B | (m) | $1.30B | $50.02B | (m) |
| 2022-09-30 | (m) | (m) | $763.80M | $18.72B | (m) | (m) | $48.66B | (m) |
| 2022-06-30 | (m) | (m) | $768.20M | $19.21B | (m) | (m) | $51.13B | (m) |
| 2022-03-31 | (m) | (m) | $2.61B | $18.76B | (m) | (m) | $53.47B | (m) |
| 2021-12-31 | (m) | (m) | $1.88B | $19.72B | (m) | $739.40M | $54.84B | (m) |
| 2021-09-30 | (m) | (m) | $1.91B | $19.85B | (m) | (m) | $56.07B | (m) |
| 2021-06-30 | (m) | (m) | $2.18B | $20.92B | (m) | (m) | $57.98B | (m) |
| 2021-03-31 | (m) | (m) | $2.30B | $22.10B | (m) | (m) | $58.98B | (m) |
| 2020-12-31 | (m) | (m) | $2.31B | $22.43B | (m) | $883.50M | $61.55B | (m) |
| 2020-09-27 | (m) | (m) | (m) | $11.54B | (m) | (m) | $11.41B | (m) |
| 2020-06-28 | (m) | (m) | (m) | $11.39B | (m) | (m) | $11.41B | (m) |
| 2019-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $0.00 | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |